查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1578327

全球阵发性睡眠性血红蛋白尿 (PNH) 治疗市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 170 Pages | 商品交期: 最快1-2个工作天内

价格

全球阵发性睡眠性血红蛋白尿 (PNH) 治疗市场需求预计将从 2023 年的 44.9 亿美元增至 2032 年近 123.8 亿美元，2024-2032 年研究期间复合年增长率为 11.92%。

阵发性睡眠性血红素尿症（PNH）是一种慢性血液疾病，即主要影响血液的疾病。这是一种极为罕见的骨髓干细胞疾病，影响全球 20,000 多人。这种疾病对男性和女性的影响相同。身体症状可以在任何年龄开始，通常在30-40岁之间出现。 PNH 患者唯一的治疗方法是异体干细胞移植。

市场动态

一些血液和骨髓相关疾病的增加以及老年人口的增加是推动 PNH 治疗市场成长的关键因素。除此之外，生物製剂的出现和新型疗法的采用正在进一步推动市场成长。然而，与目前可用治疗相关的副作用、医疗设备成本的增加，特别是干细胞转化所需的手术设备是抑制 PNH 市场成长的一些因素。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球阵发性睡眠性血红蛋白尿 (PNH) 治疗市场的各个细分市场进行了包容性评估。阵发性睡眠性血红蛋白尿 (PNH) 治疗产业的成长和趋势为本研究提供了整体方法。

市场区隔

阵发性睡眠性血红蛋白尿 (PNH) 治疗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人群以及即将到来的机会。

按治疗类型

  • 补体抑制剂
  • 铁疗法
  • 免疫抑制剂药物
  • 骨髓移植
  • 其他治疗类型

依给药途径

  • 口服
  • 注射用

按年龄段

  • 儿科
  • 成人

按最终用途

  • 医院
  • 专科诊所
  • 家庭护理设置
  • 其他最终用户
  • 区域分析

本节介绍区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的阵发性睡眠性血红蛋白尿 (PNH) 治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。阵发性睡眠性血红蛋白尿(PNH) 治疗市场的主要参与者包括安进公司(Amgen Inc.)、Apellis Pharmaceuticals Inc.、阿斯特捷利康公司(AstraZeneca Plc)、美国国家儿童医院(Children's National Hospital)、罗氏有限公司(F. Hoffmann-La Roche Ltd.)、纪念斯隆凯特琳癌症中心(Memorial Sloan Kettering Cancer Center)、诺华公司(Novartis AG)、辉瑞公司(Pfizer Inc.) .、Regeneron Pharmaceuticals Inc.、Teva Pharmaceuticals Industries Ltd.、UCLA Health、罗彻斯特大学医学中心。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：阵发性睡眠性血红素尿症 (PNH) 治疗 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按治疗类型进行的市场吸引力分析
    • 按给药途径进行的市场吸引力分析
    • 按年龄组别分類的市场吸引力分析
    • 按最终用途分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球阵发性睡眠性血红素尿症 (PNH) 治疗市场分析：依治疗类型

  • 按治疗类型概述
  • 按治疗类型进行历史和预测数据分析
  • 补体抑制剂
  • 铁疗法
  • 免疫抑制剂药物
  • 骨髓移植
  • 其他治疗类型

第 6 章：全球阵发性睡眠性血红素尿症 (PNH) 治疗市场分析：依给药途径

  • 依给药途径概述
  • 按给药途径进行历史和预测资料分析
  • 口服
  • 注射用

第 7 章：全球阵发性睡眠性血红蛋白尿 (PNH) 治疗市场分析：按年龄层划分

  • 按年龄组别概述
  • 按年龄组别进行的历史和预测资料分析
  • 儿科
  • 成人

第 8 章：全球阵发性睡眠性血红蛋白尿 (PNH) 治疗市场分析：依最终用途分类

  • 按最终用途分类的概述
  • 按最终用途进行历史和预测资料分析
  • 医院
  • 专科诊所
  • 家庭护理设置
  • 其他最终用户

第 9 章：全球阵发性睡眠性血红蛋白尿 (PNH) 治疗市场分析：按地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 10 章：阵发性睡眠性血红素尿症 (PNH) 治疗公司的竞争格局

  • 阵发性睡眠性血红素尿症 (PNH) 治疗市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 11 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Amgen Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Apellis Pharmaceuticals Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • AstraZeneca Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Children'S National Hospital
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • F. Hoffmann-La Roche Ltd.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Memorial Sloan Kettering Cancer Center
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Novartis AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Pfizer Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Regeneron Pharmaceuticals Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Teva Pharmaceuticals Industries Ltd.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • UCLA Health
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • University Of Rochester Medical Center
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR11210464

The global demand for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market is presumed to reach the market size of nearly USD 12.38 Billion by 2032 from USD 4.49 Billion in 2023 with a CAGR of 11.92% under the study period 2024-2032.

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a chronic hematological disorder, i.e. disorder which primarily affects the blood. It is an ultra-rare disease of bone marrow stem cells which affects more than 20,000 people globally. This disease affects men and women equally. Physical symptoms can begin at any age, they usually develop between 30-40 years of age. The only curative therapy for PNH patients is allogeneic stem cell transplantation.

MARKET DYNAMICS

The rise in a number of blood and bone marrow related disorders and increase in geriatric population are the key factors which drive the market growth of PNH treatment market. In addition to this, the emergence of biologics and adoption of novel therapeutics are further pushing the market growth. However, adverse effects associated with currently available treatments, increase in the cost of medical equipment, specifically surgical equipment required for stem cell transformation are some factors that restrain market growth of PNH.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment. The growth and trends of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Type

  • Complement Inhibitors
  • Iron Therapy
  • Immunosuppressant Drugs
  • Bone Marrow Transplantation
  • Other Treatment Types

By Route Of Administration

  • Oral
  • Parenteral

By Age Group

  • Pediatric
  • Adult

By End-Use

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Other End-Users
  • Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market include Amgen Inc., Apellis Pharmaceuticals Inc., AstraZeneca Plc, Children'S National Hospital, F. Hoffmann-La Roche Ltd., Memorial Sloan Kettering Cancer Center, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Teva Pharmaceuticals Industries Ltd., UCLA Health, University Of Rochester Medical Center. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Type
    • 3.7.2 Market Attractiveness Analysis By Route Of Administration
    • 3.7.3 Market Attractiveness Analysis By Age Group
    • 3.7.4 Market Attractiveness Analysis By End-Use
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

  • 5.1. Overview By Treatment Type
  • 5.2. Historical and Forecast Data Analysis By Treatment Type
  • 5.3. Complement Inhibitors Historic and Forecast Sales By Regions
  • 5.4. Iron Therapy Historic and Forecast Sales By Regions
  • 5.5. Immunosuppressant Drugs Historic and Forecast Sales By Regions
  • 5.6. Bone Marrow Transplantation Historic and Forecast Sales By Regions
  • 5.7. Other Treatment Types Historic and Forecast Sales By Regions

6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1. Overview By Route Of Administration
  • 6.2. Historical and Forecast Data Analysis By Route Of Administration
  • 6.3. Oral Historic and Forecast Sales By Regions
  • 6.4. Parenteral Historic and Forecast Sales By Regions

7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY AGE GROUP

  • 7.1. Overview By Age Group
  • 7.2. Historical and Forecast Data Analysis By Age Group
  • 7.3. Pediatric Historic and Forecast Sales By Regions
  • 7.4. Adult Historic and Forecast Sales By Regions

8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY END-USE

  • 8.1. Overview By End-Use
  • 8.2. Historical and Forecast Data Analysis By End-Use
  • 8.3. Hospitals Historic and Forecast Sales By Regions
  • 8.4. Specialty Clinics Historic and Forecast Sales By Regions
  • 8.5. Homecare Settings Historic and Forecast Sales By Regions
  • 8.6. Other End-Users Historic and Forecast Sales By Regions

9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT COMPANIES

  • 10.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Amgen Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Apellis Pharmaceuticals Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. AstraZeneca Plc
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Children'S National Hospital
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. F. Hoffmann-La Roche Ltd.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Memorial Sloan Kettering Cancer Center
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Novartis AG
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Pfizer Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Regeneron Pharmaceuticals Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Teva Pharmaceuticals Industries Ltd.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. UCLA Health
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. University Of Rochester Medical Center
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Type (USD MN)
  • Complement Inhibitors Market Sales By Geography (USD MN)
  • Iron Therapy Market Sales By Geography (USD MN)
  • Immunosuppressant Drugs Market Sales By Geography (USD MN)
  • Bone Marrow Transplantation Market Sales By Geography (USD MN)
  • Other Treatment Types Market Sales By Geography (USD MN)
  • Analysis By Route Of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Analysis By Age Group (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Analysis By End-Use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Homecare Settings Market Sales By Geography (USD MN)
  • Other End-Users Market Sales By Geography (USD MN)
  • Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Type
  • Market Attractiveness Analysis By Route Of Administration
  • Market Attractiveness Analysis By Age Group
  • Market Attractiveness Analysis By End-Use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Type (USD MN)
  • Complement Inhibitors Market Sales By Geography (USD MN)
  • Iron Therapy Market Sales By Geography (USD MN)
  • Immunosuppressant Drugs Market Sales By Geography (USD MN)
  • Bone Marrow Transplantation Market Sales By Geography (USD MN)
  • Other Treatment Types Market Sales By Geography (USD MN)
  • Global Market Analysis By Route Of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Global Market Analysis By Age Group (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Global Market Analysis By End-Use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Homecare Settings Market Sales By Geography (USD MN)
  • Other End-Users Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.